Emergent BioSolutions Inc. appointed John D. Fowler, Jr. as a Class II independent director, effective March 1, 2026. Mr. Fowler will serve as a member of the Board's Audit and Finance Committee. His initial term will expire at the company's 2026 annual meeting of stockholders. Mr. Fowler brings over three decades of leadership experience in healthcare and financial services, including senior roles at Wells Fargo Securities, Deutsche Bank, JPMorgan, and Salomon Brothers. He will receive an initial restricted stock unit grant valued at $270,000, vesting in three equal installments over three years. Annual compensation includes a $70,000 cash retainer for Board service, an additional $15,000 for Audit and Finance Committee service, and an annual equity award valued at $270,000 (75% RSUs, 25% options), subject to proration in his first year of service.